UNSPSC 51401529: Flutoprazepam

This classification denotes an anticonvulsant agent with the molecular formula C19H16ClFN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2GHY1101MM, chemically known as 7-chloro-1-(cyclopropylmethyl)-5-(o-fluorophenyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as flutoprazepam, which bears US NIH Compound Identifier 3400. European Medicines Agency schedules Flutoprazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07764MIG.

UNSPSC 51401529 Flutoprazepam, a Commodity code, shows minimal recent state and local procurement activity aligned to the specific drug designation. The three recent opportunities posted under this code—naloxone procurement by Seminole County, Florida; a Texas HHS Commission RFI on direct-to-manufacturer pharmacy programs; and a Minnesota cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—address broader pharmaceutical supply, pharmacy benefit management, and drug distribution infrastructure rather than flutoprazepam specifically. State and local governments buying under this code tier appear focused on community health support, pharmacy benefit optimization, and supplier relationship structures across state health and human services agencies, county health departments, and multistate cooperative purchasing alliances. The work involves sourcing pharmaceuticals through wholesaler networks, managing NDC-level product specifications, and negotiating pricing and compliance frameworks with manufacturers and distributors.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County's IFB (response due July 26, 2023, per posting date discrepancy in source) procures 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring E-Verify compliance and fixed-fee bidding. The Texas Health and Human Services Commission issued an RFI (due April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson—with pricing weighted 75 percent of evaluation and a 3 percent administrative fee. Vendors must maintain cGMP and DSCSA compliance, supply NDC-specific product data, and sustain relationships with at least two authorized wholesalers. The code does not demonstrate concentrated activity under the flutoprazepam designation itself; vendors should verify whether opportunities tagged to this code align with their actual product lines before pursuing.